In the STOPAH trial, prednisolone was associated with a reduction in 28-day mortality that did not reach statistical significance and no improvement in outcomes at 90 days or one year.
← all excerpts
Design of a multicenter randomized clinical trial for treatment of Alcohol-Associated Hepatitis.
1
—
—